BIO-RAD LABORATORIES -CL B (BIO.B) Stock Fundamental Analysis
USA - NYSE:BIO.B - US0905721082 - Common Stock
247.05 USD
-10.7 (-4.15%)
BIO.B gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 55 industry peers in the Life Sciences Tools & Services industry. While BIO.B has a great health rating, its profitability is only average at the moment. BIO.B is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
BIO.B had positive earnings in the past year.
BIO.B had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: BIO.B reported negative net income in multiple years.
BIO.B had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of BIO.B (-22.71%) is worse than 65.45% of its industry peers.
The Return On Equity of BIO.B (-32.40%) is worse than 60.00% of its industry peers.
BIO.B has a Return On Invested Capital of 2.70%. This is in the better half of the industry: BIO.B outperforms 61.82% of its industry peers.
The Average Return On Invested Capital over the past 3 years for BIO.B is significantly below the industry average of 15.96%.
The last Return On Invested Capital (2.70%) for BIO.B is above the 3 year average (2.69%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -22.71% | ||
| ROE | -32.4% | ||
| ROIC | 2.7% |
ROA(3y)-17.25%
ROA(5y)0.31%
ROE(3y)-24.36%
ROE(5y)-0.68%
ROIC(3y)2.69%
ROIC(5y)2.68%
1.3 Margins
With a decent Operating Margin value of 12.14%, BIO.B is doing good in the industry, outperforming 69.09% of the companies in the same industry.
In the last couple of years the Operating Margin of BIO.B has remained more or less at the same level.
With a decent Gross Margin value of 53.68%, BIO.B is doing good in the industry, outperforming 63.64% of the companies in the same industry.
In the last couple of years the Gross Margin of BIO.B has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 12.14% | ||
| PM (TTM) | N/A | ||
| GM | 53.68% |
OM growth 3Y-15.52%
OM growth 5Y1.14%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.9%
GM growth 5Y-0.31%
2. Health
2.1 Basic Checks
BIO.B has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
BIO.B has less shares outstanding than it did 1 year ago.
BIO.B has less shares outstanding than it did 5 years ago.
The debt/assets ratio for BIO.B is higher compared to a year ago.
2.2 Solvency
BIO.B has an Altman-Z score of 3.21. This indicates that BIO.B is financially healthy and has little risk of bankruptcy at the moment.
BIO.B has a Altman-Z score of 3.21. This is in the better half of the industry: BIO.B outperforms 65.45% of its industry peers.
BIO.B has a debt to FCF ratio of 3.62. This is a good value and a sign of high solvency as BIO.B would need 3.62 years to pay back of all of its debts.
BIO.B has a Debt to FCF ratio of 3.62. This is in the better half of the industry: BIO.B outperforms 70.91% of its industry peers.
BIO.B has a Debt/Equity ratio of 0.18. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.18, BIO.B perfoms like the industry average, outperforming 58.18% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | 3.62 | ||
| Altman-Z | 3.21 |
ROIC/WACC0.33
WACC8.13%
2.3 Liquidity
BIO.B has a Current Ratio of 5.99. This indicates that BIO.B is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 5.99, BIO.B belongs to the best of the industry, outperforming 81.82% of the companies in the same industry.
A Quick Ratio of 4.43 indicates that BIO.B has no problem at all paying its short term obligations.
The Quick ratio of BIO.B (4.43) is better than 70.91% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.99 | ||
| Quick Ratio | 4.43 |
3. Growth
3.1 Past
BIO.B shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -7.11%.
BIO.B shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 7.84% yearly.
Looking at the last year, BIO.B shows a decrease in Revenue. The Revenue has decreased by -3.92% in the last year.
BIO.B shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 2.11% yearly.
EPS 1Y (TTM)-7.11%
EPS 3Y-13.02%
EPS 5Y7.84%
EPS Q2Q%-16.08%
Revenue 1Y (TTM)-3.92%
Revenue growth 3Y-4.24%
Revenue growth 5Y2.11%
Sales Q2Q%2.06%
3.2 Future
BIO.B is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -4.33% yearly.
BIO.B is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 1.35% yearly.
EPS Next Y-17.35%
EPS Next 2Y-4.67%
EPS Next 3Y1.5%
EPS Next 5Y-4.33%
Revenue Next Year-2.19%
Revenue Next 2Y0.57%
Revenue Next 3Y1.77%
Revenue Next 5Y1.35%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 24.56 indicates a rather expensive valuation of BIO.B.
BIO.B's Price/Earnings ratio is a bit cheaper when compared to the industry. BIO.B is cheaper than 72.73% of the companies in the same industry.
BIO.B is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 27.27, which is the current average of the S&P500 Index.
With a Price/Forward Earnings ratio of 26.37, BIO.B can be considered very expensive at the moment.
Compared to the rest of the industry, the Price/Forward Earnings ratio of BIO.B indicates a somewhat cheap valuation: BIO.B is cheaper than 69.09% of the companies listed in the same industry.
BIO.B is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 22.77, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 24.56 | ||
| Fwd PE | 26.37 |
4.2 Price Multiples
81.82% of the companies in the same industry are more expensive than BIO.B, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 20.25 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)3.13
EPS Next 2Y-4.67%
EPS Next 3Y1.5%
5. Dividend
5.1 Amount
No dividends for BIO.B!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NYSE:BIO.B (7/23/2025, 8:05:22 PM)
247.05
-10.7 (-4.15%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners89.78%
Inst Owner Change-26.18%
Ins Owners3.67%
Ins Owner ChangeN/A
Market Cap6.72B
Analysts76.36
Price Target369.39 (49.52%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)19.53%
Min EPS beat(2)0.1%
Max EPS beat(2)38.97%
EPS beat(4)4
Avg EPS beat(4)40.99%
Min EPS beat(4)0.1%
Max EPS beat(4)72.05%
EPS beat(8)7
Avg EPS beat(8)21.55%
EPS beat(12)8
Avg EPS beat(12)14.41%
EPS beat(16)12
Avg EPS beat(16)19.4%
Revenue beat(2)1
Avg Revenue beat(2)-0.8%
Min Revenue beat(2)-2.71%
Max Revenue beat(2)1.11%
Revenue beat(4)2
Avg Revenue beat(4)-0.33%
Min Revenue beat(4)-2.71%
Max Revenue beat(4)2.41%
Revenue beat(8)2
Avg Revenue beat(8)-2.22%
Revenue beat(12)3
Avg Revenue beat(12)-1.99%
Revenue beat(16)6
Avg Revenue beat(16)0.12%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-3.36%
EPS NQ rev (3m)-30.61%
EPS NY rev (1m)-2.06%
EPS NY rev (3m)-12.45%
Revenue NQ rev (1m)-0.05%
Revenue NQ rev (3m)-3.11%
Revenue NY rev (1m)-0.08%
Revenue NY rev (3m)-1.58%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 24.56 | ||
| Fwd PE | 26.37 | ||
| P/S | 2.65 | ||
| P/FCF | 20.25 | ||
| P/OCF | 13.05 | ||
| P/B | 1.01 | ||
| P/tB | 1.13 | ||
| EV/EBITDA | N/A |
EPS(TTM)10.06
EY4.07%
EPS(NY)9.37
Fwd EY3.79%
FCF(TTM)12.2
FCFY4.94%
OCF(TTM)18.93
OCFY7.66%
SpS93.39
BVpS245.46
TBVpS219.33
PEG (NY)N/A
PEG (5Y)3.13
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -22.71% | ||
| ROE | -32.4% | ||
| ROCE | 3.42% | ||
| ROIC | 2.7% | ||
| ROICexc | 3.31% | ||
| ROICexgc | 3.67% | ||
| OM | 12.14% | ||
| PM (TTM) | N/A | ||
| GM | 53.68% | ||
| FCFM | 13.07% |
ROA(3y)-17.25%
ROA(5y)0.31%
ROE(3y)-24.36%
ROE(5y)-0.68%
ROIC(3y)2.69%
ROIC(5y)2.68%
ROICexc(3y)3.19%
ROICexc(5y)3.05%
ROICexgc(3y)3.46%
ROICexgc(5y)3.26%
ROCE(3y)3.41%
ROCE(5y)3.39%
ROICexcg growth 3Y8.28%
ROICexcg growth 5Y0.09%
ROICexc growth 3Y5.96%
ROICexc growth 5Y-0.55%
OM growth 3Y-15.52%
OM growth 5Y1.14%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.9%
GM growth 5Y-0.31%
F-Score5
Asset Turnover0.27
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | 3.62 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | 7.2% | ||
| Interest Coverage | -6.57 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 5.99 | ||
| Quick Ratio | 4.43 | ||
| Altman-Z | 3.21 |
F-Score5
WACC8.13%
ROIC/WACC0.33
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)5.76%
Cap/Sales(5y)5.22%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-7.11%
EPS 3Y-13.02%
EPS 5Y7.84%
EPS Q2Q%-16.08%
EPS Next Y-17.35%
EPS Next 2Y-4.67%
EPS Next 3Y1.5%
EPS Next 5Y-4.33%
Revenue 1Y (TTM)-3.92%
Revenue growth 3Y-4.24%
Revenue growth 5Y2.11%
Sales Q2Q%2.06%
Revenue Next Year-2.19%
Revenue Next 2Y0.57%
Revenue Next 3Y1.77%
Revenue Next 5Y1.35%
EBIT growth 1Y-9.77%
EBIT growth 3Y-19.1%
EBIT growth 5Y3.28%
EBIT Next Year22.43%
EBIT Next 3Y13.71%
EBIT Next 5Y6.41%
FCF growth 1Y162.24%
FCF growth 3Y-20.82%
FCF growth 5Y-5.84%
OCF growth 1Y112.81%
OCF growth 3Y-12.08%
OCF growth 5Y-0.13%